Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018

Summary

Global Markets Direct’s new report, "Turkey In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2018” provides key market data on the Turkey In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Turkey In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Turkey In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 11
2.1 What is This Report About? 11
3 In Vitro Diagnostics In Turkey 12
3.1 In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, 2004-2018 12
3.2 In Vitro Diagnostics, Turkey, Company Share (2010-2011) 18
4 Clinical Chemistry In Turkey 20
4.1 Clinical Chemistry Overall Revenue, (2004-2018) 20
4.1.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 24
4.1.2 Urine Analysis, Revenue (2004-2018) 28
4.2 Clinical Chemistry Distribution Share (2010-2011) 32
4.3 Clinical Chemistry, Turkey, Company Share (2010-2011) 33
5 Genetic Testing In Turkey 35
5.1 Genetic Testing Overall Revenue, (2004-2018) 35
5.2 Genetic Testing Distribution Share (2010-2011) 39
5.3 Genetic Testing, Turkey, Company Share (2010-2011) 40
6 Haematology In Turkey 42
6.1 Haematology Overall Revenue, (2004-2018) 42
6.1.1 Haematology Reagents, Revenue, (2004-2018) 46
6.1.2 Immunohaematology, Revenue (2004-2018) 50
6.1.3 Haemostasis, Revenue (2004-2018) 54
6.1.4 Haematology Rapid Tests, Revenue (2004-2018) 58
6.1.5 Haematology Cell Counters, Revenue (2004-2018) 62
6.2 Haematology Distribution Share (2010-2011) 66
6.3 Haematology, Turkey, Company Share (2010-2011) 67
7 Histology And Cytology In Turkey 69
7.1 Histology And Cytology Overall Revenue, (2004-2018) 69
7.2 Histology And Cytology Distribution Share (2010-2011) 73
7.3 Histology And Cytology, Turkey, Company Share (2010-2011) 74
8 Immuno Chemistry In Turkey 76
8.1 Immuno Chemistry Overall Revenue, (2004-2018) 76
8.1.1 Disease Specific Immunochemistry, Revenue (2004-2018) 80
8.1.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 84
8.1.3 Endocrinology Tests, Revenue (2004-2018) 88
8.1.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 92
8.1.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 96
8.1.6 Immunochemistry Analyzers, Revenue (2004-2018) 100
8.2 Immuno Chemistry Distribution Share (2010-2011) 104
8.3 Immuno Chemistry, Turkey, Company Share (2010-2011) 105
9 Infectious Immunology In Turkey 107
9.1 Infectious Immunology Overall Revenue, (2004-2018) 107
9.1.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 111
9.2 Infectious Immunology Distribution Share (2010-2011) 115
9.3 Infectious Immunology, Turkey, Company Share (2010-2011) 116
10 Microbiology Culture In Turkey 118
10.1 Microbiology Culture Overall Revenue, (2004-2018) 118
10.1.1 Microbiology Analyzers, Revenue (2004-2018) 122
10.2 Microbiology Culture Distribution Share (2010-2011) 126
10.3 Microbiology Culture, Turkey, Company Share (2010-2011) 127
11 Overview of Key Companies in Turkey In Vitro Diagnostics Market 129
11.1 F. Hoffmann-La Roche Ltd. 129
11.1.1 Company Overview 129
11.2 Siemens Healthcare 129
11.2.1 Company Overview 129
11.3 Abbott Laboratories 130
11.3.1 Company Overview 130
11.4 Beckman Coulter, Inc. 130
11.4.1 Company Overview 130
11.5 bioMerieux S.A. 131
11.5.1 Company Overview 131
11.6 Ortho-Clinical Diagnostics Inc. 131
11.6.1 Company Overview 131
11.7 Becton, Dickinson and Company 132
11.7.1 Company Overview 132
11.8 Sysmex Corporation 132
11.8.1 Company Overview 132
11.9 Bio-Rad Laboratories, Inc. 133
11.9.1 Company Overview 133
11.10 Diagnostica Stago, Inc. 133
11.10.1 Company Overview 133
11.11 Danaher Corporation 134
11.11.1 Company Overview 134
11.12 Mindray Medical International Limited 134
11.12.1 Company Overview 134
11.13 Qiagen N.V. 135
11.13.1 Company Overview 135
11.14 DiaSorin S.p.A 135
11.14.1 Company Overview 135
11.15 Thermo Fisher Scientific Inc. 136
11.15.1 Company Overview 136
11.16 Horiba, Ltd. 136
11.16.1 Company Overview 136
11.17 PerkinElmer, Inc. 137
11.17.1 Company Overview 137
11.18 Olympus Corporation 137
11.18.1 Company Overview 137
11.19 Gen-Probe Incorporated 138
11.19.1 Company Overview 138
11.20 Life Technologies Corporation 138
11.20.1 Company Overview 138
11.21 Grifols, S.A. 139
11.21.1 Company Overview 139
11.22 Alere Inc. 139
11.22.1 Company Overview 139
11.23 Immucor, Inc. 140
11.23.1 Company Overview 140
11.24 Cellestis Limited 140
11.24.1 Company Overview 140
11.25 Hologic, Inc. 141
11.25.1 Company Overview 141
11.26 Phadia AB 141
11.26.1 Company Overview 141
12 Appendix 142
12.1 Global Markets Direct Research Methodology 142
12.2 Definitions of Markets Covered in the Report 143
12.2.1 In Vitro Diagnostics 143
12.3 Secondary Research 154
12.4 Primary Research 154
12.5 Models 155
12.6 Forecasts 155
12.7 Expert Panel Validation 155
12.8 Currency Conversion 156
12.9 Contact Us 156
12.10 Disclaimer 156

1.1 List of Tables
Table 1: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, 2004-2018 13
Table 2: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, Historic, 2004-2011 15
Table 3: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 17
Table 4: In Vitro Diagnostics, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 19
Table 5: Clinical Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 21
Table 6: Clinical Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 23
Table 7: Clinical Chemisty Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 25
Table 8: Clinical Chemisty Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 27
Table 9: Urine Analysis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 29
Table 10: Urine Analysis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 31
Table 11: Clinical Chemistry, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 32
Table 12: Clinical Chemistry, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 34
Table 13: Genetic Testing, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 36
Table 14: Genetic Testing, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 38
Table 15: Genetic Testing, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 39
Table 16: Genetic Testing, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 41
Table 17: Haematology, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 43
Table 18: Haematology, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 45
Table 19: Haematology Reagents, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 47
Table 20: Haematology Reagents, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 49
Table 21: Immunohaematology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 51
Table 22: Immunohaematology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 53
Table 23: Haemostasis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55
Table 24: Haemostasis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57
Table 25: Haematology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59
Table 26: Haematology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61
Table 27: Haematology Cell Counters, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 63
Table 28: Haematology Cell Counters, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 65
Table 29: Haematology, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 66
Table 30: Haematology, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 68
Table 31: Histology And Cytology, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 70
Table 32: Histology And Cytology, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 72
Table 33: Histology And Cytology, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 73
Table 34: Histology And Cytology, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 75
Table 35: Immuno Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 77
Table 36: Immuno Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 79
Table 37: Disease Specific Immunochemistry, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 81
Table 38: Disease Specific Immunochemistry, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 83
Table 39: Drugs of Abuse / Toxicology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 85
Table 40: Drugs of Abuse / Toxicology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 87
Table 41: Endocrinology Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 89
Table 42: Endocrinology Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 91
Table 43: Immunochemistry Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 93
Table 44: Immunochemistry Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 95
Table 45: Therapeutic Drug Monitoring, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 97
Table 46: Therapeutic Drug Monitoring, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 99
Table 47: Immunochemistry Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 101
Table 48: Immunochemistry Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 103
Table 49: Immuno Chemistry, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 104
Table 50: Immuno Chemistry, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 106
Table 51: Infectious Immunology, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 108
Table 52: Infectious Immunology, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 110
Table 53: Infectious Immunology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 112
Table 54: Infectious Immunology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 114
Table 55: Infectious Immunology, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 115
Table 56: Infectious Immunology, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 117
Table 57: Microbiology Culture, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 119
Table 58: Microbiology Culture, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 121
Table 59: Microbiology Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 123
Table 60: Microbiology Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 125
Table 61: Microbiology Culture, Turkey, Distribution Share by Revenue ($m), USD Constant, 2010-2011 126
Table 62: Microbiology Culture, Turkey, Company Share by Revenue ($m), USD Constant, 2010-2011 128

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, 2004-2018 12
Figure 2: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, Historic, 2004-2011 14
Figure 3: In Vitro Diagnostics, Turkey, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 16
Figure 4: In Vitro Diagnostics, Turkey, Company Share (%), 2011 18
Figure 5: Clinical Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 20
Figure 6: Clinical Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 22
Figure 7: Clinical Chemisty Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 24
Figure 8: Clinical Chemisty Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 26
Figure 9: Urine Analysis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 28
Figure 10: Urine Analysis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 30
Figure 11: Clinical Chemistry, Turkey, Company Share (%), 2011 33
Figure 12: Genetic Testing, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 35
Figure 13: Genetic Testing, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 37
Figure 14: Genetic Testing, Turkey, Company Share (%), 2011 40
Figure 15: Haematology, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 42
Figure 16: Haematology, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 44
Figure 17: Haematology Reagents, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 46
Figure 18: Haematology Reagents, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 48
Figure 19: Immunohaematology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 50
Figure 20: Immunohaematology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 52
Figure 21: Haemostasis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 54
Figure 22: Haemostasis, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 56
Figure 23: Haematology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 58
Figure 24: Haematology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 60
Figure 25: Haematology Cell Counters, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 62
Figure 26: Haematology Cell Counters, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 64
Figure 27: Haematology, Turkey, Company Share (%), 2011 67
Figure 28: Histology And Cytology, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 69
Figure 29: Histology And Cytology, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 71
Figure 30: Histology And Cytology, Turkey, Company Share (%), 2011 74
Figure 31: Immuno Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 76
Figure 32: Immuno Chemistry, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 78
Figure 33: Disease Specific Immunochemistry, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 80
Figure 34: Disease Specific Immunochemistry, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 82
Figure 35: Drugs of Abuse / Toxicology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 84
Figure 36: Drugs of Abuse / Toxicology, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 86
Figure 37: Endocrinology Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 88
Figure 38: Endocrinology Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 90
Figure 39: Immunochemistry Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 92
Figure 40: Immunochemistry Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 94
Figure 41: Therapeutic Drug Monitoring, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 96
Figure 42: Therapeutic Drug Monitoring, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 98
Figure 43: Immunochemistry Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 100
Figure 44: Immunochemistry Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 102
Figure 45: Immuno Chemistry, Turkey, Company Share (%), 2011 105
Figure 46: Infectious Immunology, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 107
Figure 47: Infectious Immunology, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 109
Figure 48: Infectious Immunology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 111
Figure 49: Infectious Immunology Rapid Tests, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 113
Figure 50: Infectious Immunology, Turkey, Company Share (%), 2011 116
Figure 51: Microbiology Culture, Turkey, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 118
Figure 52: Microbiology Culture, Turkey, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 120
Figure 53: Microbiology Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 122
Figure 54: Microbiology Analyzers, Turkey, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 124
Figure 55: Microbiology Culture, Turkey, Company Share (%), 2011 127
Figure 56: Global Markets Direct Methodology 142